CD8A and neoplasm: In vivo, a single i.t. VMG dose completely inhibited Ewing sarcoma xenografts, whereas in immunocompetent fibrosarcoma models, VMG induced substantial CD8+ T cell infiltration despite limited tumor regression, demonstrating both safety and immune engagement [44].